TuHURA Biosciences, Inc. (HURA) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.88
↑+153% vs avg
5yr avg: 2.33
30Y Low0.0·High5.2
ROE
↑
-169.2%
↓+38% vs avg
5yr avg: -274.2%
30Y Low-461%·High-141%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HURA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
TuHURA Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $164M | $36M | $76M | $4M | $318904 | $709640 | $2M | $205299 | $94880 | $407056 | $787739 |
| Enterprise Value | $161M | $33M | $64M | $3M | $-13795390 | $-4192345 | $-8858222 | $-2186701 | $-3623879 | $-5564939 | $-5798275 |
| P/E Ratio → | -4.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.88 | 1.73 | 5.23 | — | 0.03 | — | 0.16 | 0.78 | 0.05 | 0.07 | 0.12 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HURA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
HURA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -169.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -169.2% | -169.2% | -332.7% | -154.9% | -253.5% | -460.9% | -706.3% | -818.3% | -217.4% | -185.4% | -141.3% |
| ROA | -127.1% | -127.1% | -178.2% | -85.1% | -135.6% | -227.2% | -464.8% | -261.7% | -144.9% | -148.7% | -113.3% |
| ROIC | -239.0% | -239.0% | — | — | — | — | — | — | — | — | — |
| ROCE | -176.3% | -176.3% | -229.2% | -129.1% | -255.6% | -453.0% | -391.3% | -730.2% | -226.9% | -185.6% | -134.9% |
HURA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $502668, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | — | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.85 | — | -1.15 | — | -1.00 | -9.10 | -1.89 | -1.10 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -47.06 | -47.06 | -4.24 | -445.21 | — | -36.04 | -318.15 | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($502668)
HURA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.78x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.16x to 0.78x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | 0.78 | 3.68 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Quick Ratio | 0.78 | 0.78 | 3.64 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Cash Ratio | 0.61 | 0.61 | 2.37 | 1.02 | 4.96 | 0.78 | 3.79 | 0.89 | 1.80 | 3.64 | 5.05 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
HURA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
TuHURA Biosciences, Inc. returns 0.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.0% | 0.0% | — | — | — | 1.1% | 0.5% | 3.9% | 8.8% | 2.1% | 1.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 1.1% | 0.5% | 3.9% | 8.8% | 2.1% | 1.1% |
| Shares Outstanding | — | $48M | $19M | $752914 | $46285 | $27829 | $14791 | $5968 | $1471 | $1192 | $688 |
Peer Comparison
Compare HURA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HURAYou | $164M | -4.1 | — | — | — | — | -169.2% | -239.0% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRIS | $82M | -0.7 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 IOVA | $1B | -3.6 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.2% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HURA — Frequently Asked Questions
Quick answers to the most common questions about buying HURA stock.
What is TuHURA Biosciences, Inc.'s P/E ratio?
TuHURA Biosciences, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
What is TuHURA Biosciences, Inc.'s ROE?
TuHURA Biosciences, Inc.'s return on equity (ROE) is -169.2%. The historical average is -261.6%.
Is HURA stock overvalued?
Based on historical data, TuHURA Biosciences, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is TuHURA Biosciences, Inc.'s dividend yield?
TuHURA Biosciences, Inc.'s current dividend yield is 0.01%.